



## Medical Policy:

### Duchenne Muscular Dystrophy Drugs (Amodys 45™, Exondys 51®, Vyondys 53®, and Viltepso®) – MEDICAID ONLY

POLICY NUMBER	LAST REVIEW	ORIGIN DATE
MG.MM.PH.349	March 19, 2024	February 28, 2022

**Medical Guideline Disclaimer Property of EmblemHealth. All rights reserved.**

Property of EmblemHealth. All rights reserved. The treating physician or primary care provider must submit to EmblemHealth the clinical evidence that the patient meets the criteria for the treatment or surgical procedure. Without this documentation and information, EmblemHealth will not be able to properly review the request for prior authorization. The clinical review criteria expressed below reflects how EmblemHealth determines whether certain services or supplies are medically necessary. EmblemHealth established the clinical review criteria based upon a review of currently available clinical information (including clinical outcome studies in the peer-reviewed published medical literature, regulatory status of the technology, evidence-based guidelines of public health and health research agencies, evidence-based guidelines and positions of leading national health professional organizations, views of physicians practicing in relevant clinical areas, and other relevant factors). EmblemHealth expressly reserves the right to revise these conclusions as clinical information changes and welcomes further relevant information. Each benefit program defines which services are covered. The conclusion that a particular service or supply is medically necessary does not constitute a representation or warranty that this service or supply is covered and/or paid for by EmblemHealth, as some programs exclude coverage for services or supplies that EmblemHealth considers medically necessary. If there is a discrepancy between this guideline and a member's benefits program, the benefits program will govern. In addition, coverage may be mandated by applicable legal requirements of a state, the Federal Government or the Centers for Medicare & Medicaid Services (CMS) for Medicare and Medicaid members. All coding and web site links are accurate at time of publication. EmblemHealth Services Company LLC, ("EmblemHealth") has adopted the herein policy in providing management, administrative and other services to, EmblemHealth Plan, Inc., EmblemHealth Insurance Company, EmblemHealth Services Company, LLC and Health Insurance Plan of Greater New York (HIP), ConnectiCare, Inc., ConnectiCare Insurance Company, Inc. ConnectiCare Benefits, Inc., and ConnectiCare of Massachusetts, Inc. related to health benefit plans offered by these entities. All of the aforementioned entities are affiliated companies under common control of EmblemHealth Inc.

## Definitions

Duchenne Muscular Dystrophy (DMD) is an inherited disorder that results in a deficiency of dystrophin causing a loss of muscle function and weakness. DMD primarily affects males and is the most common, and severe, form of muscular dystrophy in children. Symptom onset usually occurs between the ages of 3 and 5. It is one of more than thirty forms of muscular dystrophy.

The DMD gene provides instructions for making the protein dystrophin. Dystrophin, a protein that protects muscles from deterioration, is located primarily in skeletal and heart muscle

Amondys 45 (casimersen), Exondys 51 (eteplirsen), Vyondys 53 (golodirsen), and Viltepso (viltolarsen) are all antisense oligonucleotides which bind to specific exon's of dystrophin pre-mRNA. The result yields production of a shortened, but partially functionally dystrophin protein as seen in less severe forms of muscular dystrophy.

## Length of Authorization

Approvals will be granted for 12 months

## Dosing Limits [Medical Benefit]

1. Amondys, Exondys, and Vyondys 30mg/kg once weekly
2. Viltepsa 80mg/kg once weekly

## Guideline

### I. Initial Approval Criteria

1. **Duchenne Muscular Dystrophy (DMD);** Approve if all (A, B, C, E, **AND** E) are met
  - A. The patient must have a diagnosis of DMD; **AND**
  - B. The patient has documentation of genetic testing that confirms the DMD gene mutation of the patient is amenable to exon 45, 51, or 53 skipping; **AND**
  - C. The patient is on a stable dose of corticosteroids prior to starting therapy **OR** has a documented reason not to be on corticosteroids; **AND**
  - D. The patient has kidney function testing prior to starting therapy (**except for eteplirsen**); **AND**
  - E. The patient is not concurrently being treated with another exon skipping therapy for DMD

### II. Renewal Criteria

1. **Duchenne Muscular Dystrophy (DMD);**
  - A. Stabilization of disease or absence of disease progression; **AND**
  - B. Absence of unacceptable toxicity from the drug.

**Limitations/Exclusions:** None

## Applicable Procedure Codes

Code	Description
J1429	Injection, golodirsen, 10 mg
J1426	Injection, casimersen, 10 mg
J1428	Injection, eteplirsen, 10 mg
J1427	Injection, viltolarsen; 10 mg

## Applicable NDCs

Code	Description
60923-0465-02	Vyondys, single use vial; 50 mg/mL powder for injection
60923-0227-02	Amondys Injection, 100 mg/2 mL (50 mg/ mL) solution in a single-dose vial
73292-0011-01	Viltepsa single-dose vials containing 250 mg/5 mL (50 mg/mL)
60923-0363-02	Exondys 51 100mg/2mL Solution J1428 Injection, Eteplirsen, 10 Mg
60923-0284-10	Exondys 51 500mg/10mL Solution J1428 Injection, Eteplirsen, 10 Mg

## ICD-10 Diagnoses

Code	Description
G71.01	Duchenne or Becker muscular dystrophy

## Revision History

Company(ies)	DATE	REVISION
EmblemHealth	3/19/2024	Annual Review: No Criteria Changes
EmblemHealth	07/11/2023	Annual Review: No Criteria Changes
EmblemHealth	2/28/2022	New Policy

## References

1. Product Information: VYONDYS 53™ intravenous injection, golodirsén intravenous injection. Sarepta Therapeutics Inc (per FDA), Cambridge, MA, 2019
2. Amondys 45 intravenous Injection [package insert]. Cambridge, MA. Sarepta Therapeutics, Inc. Updated February 2021.
3. Exondys 51 [Product Information]. Cambridge, MA. Sarepta Therapeutics, Inc. Revised September 19, 2016.
4. Product Information: VILTEPSO™ intravenous injection, viltolarsén intravenous injection. NS Pharma Inc (per manufacturer), Paramus, NJ, 2020.
5. New York State Medicaid Update January 2022 Volume 38-Number 1. Available at: [https://www.health.ny.gov/health\\_care/medicaid/program/update/2022/no01\\_2022-01.htm](https://www.health.ny.gov/health_care/medicaid/program/update/2022/no01_2022-01.htm)